[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2109189B1 - Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. - Google Patents

Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Info

Publication number
ES2109189B1
ES2109189B1 ES9600620A ES9600620A ES2109189B1 ES 2109189 B1 ES2109189 B1 ES 2109189B1 ES 9600620 A ES9600620 A ES 9600620A ES 9600620 A ES9600620 A ES 9600620A ES 2109189 B1 ES2109189 B1 ES 2109189B1
Authority
ES
Spain
Prior art keywords
genome
defective viral
virus
vectors
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9600620A
Other languages
English (en)
Other versions
ES2109189A1 (es
Inventor
Sanchez Luis Enjuanes
Parmesan Ander Izeta
Picazo Cristian Smerdou
Zunzunegui Ana Mendez
Jareno Maria Luisa Ballesteros
Sanchez Carlos M Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Farma SA
Original Assignee
Cyanamid Iberica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES9600620A priority Critical patent/ES2109189B1/es
Application filed by Cyanamid Iberica SA filed Critical Cyanamid Iberica SA
Priority to CA 2248978 priority patent/CA2248978A1/en
Priority to RU98118555A priority patent/RU2199584C2/ru
Priority to EP19970907111 priority patent/EP1008652A1/en
Priority to JP53230497A priority patent/JP3769300B2/ja
Priority to HU0000356A priority patent/HUP0000356A3/hu
Priority to US09/155,003 priority patent/US7041300B1/en
Priority to CNB971946140A priority patent/CN1318596C/zh
Priority to PL97328791A priority patent/PL188546B1/pl
Priority to KR10-1998-0707192A priority patent/KR100360327B1/ko
Priority to BR9708061A priority patent/BR9708061A/pt
Priority to EP20060013756 priority patent/EP1741789A1/en
Priority to PCT/ES1997/000059 priority patent/WO1997034008A1/es
Priority to AU19277/97A priority patent/AU729044B2/en
Publication of ES2109189A1 publication Critical patent/ES2109189A1/es
Application granted granted Critical
Publication of ES2109189B1 publication Critical patent/ES2109189B1/es
Priority to US10/444,059 priority patent/US20040052775A1/en
Priority to US11/503,214 priority patent/US20070048862A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LOS VECTORES COMPRENDEN UN GENOMA VIRAL DEFECTIVO RECOMBINANTE QUE EXPRESA AL MENOS UN ANTIGENO ADECUADO PARA LA INDUCCION DE RESPUESTAS INMUNES SISTEMICAS Y SECRETORAS. EL GENOMA VIRAL DEFECTIVO COMPRENDE EL GENOMA DE UN VIRUS PARENTAL QUE TIENE LAS SEÑALES DE RECONOCIMIENTO DE LA REPLICASA VIRAL LOCALIZADAS EN LOS EXTREMOS (3'') Y (5''), QUE COMPRENDE ADEMAS DELACIONES INTERNAS, Y EN DONDE DICHO GENOMA VIRAL DEFECTIVO DEPENDE DE UN VIRUS COMPLEMENTADOR PARA SU REPLICACION. ESTOS VECTORES SON ADECUADOS PARA FORMAR UN SISTEMA RECOMBINANTE QUE COMPRENDE (A) DICHO VECTOR DE EXPRESION, Y (B) UN VIRUS COMPLEMENTADOR QUE PROPORCIONA LAS PROTEINAS FUNCIONALES Y ESTRUCTURALES PARA LA REPLICACION Y ENCAPSIDACION DEL GENOMA DEFECTIVO. ESTE SISTEMA ES ADECUADO PARA LA ELABORACION DE VACUNAS MONO Y POLIVALENTES FRENTE AGENTES INFECCIOSOS DE DISTINTAS ESPECIES ANIMALES, ESPECIALMENTE CERDOS, PERROS Y GATOS.
ES9600620A 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. Expired - Fee Related ES2109189B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES9600620A ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
BR9708061A BR9708061A (pt) 1996-03-14 1997-03-12 Vetores baseados em genomas virais defeituosos recombinantes, e seu uso na formação de vacinas.
EP19970907111 EP1008652A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
JP53230497A JP3769300B2 (ja) 1996-03-14 1997-03-12 組換え欠陥ウイルスゲノムに基づくベクター及びワクチン製剤におけるそれらの使用
HU0000356A HUP0000356A3 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes,and their use in the formulation of vaccines
US09/155,003 US7041300B1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
CNB971946140A CN1318596C (zh) 1996-03-14 1997-03-12 基于重组缺损病毒基因组的载体及其在疫苗制剂中的应用
PL97328791A PL188546B1 (pl) 1996-03-14 1997-03-12 Wektor ekspresyjny antygenów lub przeciwciał, rekombinacyjny układ ekspresyjny i szczepionka do ochrony zwierząt
CA 2248978 CA2248978A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
RU98118555A RU2199584C2 (ru) 1996-03-14 1997-03-12 Вектор (варианты), основанный на рекомбинантном дефектном вирусном геноме, и его применение для создания препаратов вакцин
EP20060013756 EP1741789A1 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
PCT/ES1997/000059 WO1997034008A1 (es) 1996-03-14 1997-03-12 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas
AU19277/97A AU729044B2 (en) 1996-03-14 1997-03-12 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
KR10-1998-0707192A KR100360327B1 (ko) 1996-03-14 1997-03-12 재조합결함성바이러스게놈계벡터및이들벡터를백신의제형화에사용하는방법
US10/444,059 US20040052775A1 (en) 1996-03-14 2003-05-23 Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines
US11/503,214 US20070048862A1 (en) 1996-03-14 2006-08-14 Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9600620A ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Publications (2)

Publication Number Publication Date
ES2109189A1 ES2109189A1 (es) 1998-01-01
ES2109189B1 true ES2109189B1 (es) 1998-05-16

Family

ID=8294176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9600620A Expired - Fee Related ES2109189B1 (es) 1996-03-14 1996-03-14 Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.

Country Status (13)

Country Link
US (3) US7041300B1 (es)
EP (2) EP1008652A1 (es)
JP (1) JP3769300B2 (es)
KR (1) KR100360327B1 (es)
CN (1) CN1318596C (es)
AU (1) AU729044B2 (es)
BR (1) BR9708061A (es)
CA (1) CA2248978A1 (es)
ES (1) ES2109189B1 (es)
HU (1) HUP0000356A3 (es)
PL (1) PL188546B1 (es)
RU (1) RU2199584C2 (es)
WO (1) WO1997034008A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515993A (en) * 1999-06-10 2004-04-30 Merial Sas DNA vaccines for pets and sport animals
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
ES2208051B1 (es) * 2002-01-24 2005-08-16 Consejo Sup. Investig. Cientificas Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
AU2003219837B2 (en) 2002-02-21 2009-10-29 Erasmus University Medical Center Rotterdam Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
AU2005279303B2 (en) * 2004-09-03 2011-10-27 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP1650308A1 (en) * 2004-09-03 2006-04-26 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20090304738A1 (en) * 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
EP2353610A4 (en) * 2008-11-19 2013-12-11 Avi Mex S A De C V Lab RECOMBINANT INACTIVATED VIRUS VECTOR VACCINE
CN104262488B (zh) * 2014-09-24 2017-07-28 普莱柯生物工程股份有限公司 一种融合蛋白及其疫苗组合物的制备与应用
AU2021240432A1 (en) * 2020-03-27 2022-12-01 Institut Pasteur Defective interfering viral genomes
EP4136218A1 (en) * 2020-04-12 2023-02-22 Novoscope IP Limited Particles, dna & rna

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
ATE174929T1 (de) * 1993-01-23 1999-01-15 Inmunologia & Genetica Aplic Synthetischen peptiden und impfstoffe gegen parvovirus

Also Published As

Publication number Publication date
US7041300B1 (en) 2006-05-09
PL328791A1 (en) 1999-02-15
US20070048862A1 (en) 2007-03-01
CA2248978A1 (en) 1997-09-18
EP1741789A1 (en) 2007-01-10
CN1318596C (zh) 2007-05-30
HUP0000356A2 (hu) 2000-06-28
JP3769300B2 (ja) 2006-04-19
KR100360327B1 (ko) 2003-03-28
KR19990087724A (ko) 1999-12-27
HUP0000356A3 (en) 2001-09-28
RU2199584C2 (ru) 2003-02-27
US20040052775A1 (en) 2004-03-18
WO1997034008A1 (es) 1997-09-18
JP2000513565A (ja) 2000-10-17
AU729044B2 (en) 2001-01-25
ES2109189A1 (es) 1998-01-01
PL188546B1 (pl) 2005-02-28
AU1927797A (en) 1997-10-01
EP1008652A1 (en) 2000-06-14
CN1218513A (zh) 1999-06-02
BR9708061A (pt) 2000-01-04

Similar Documents

Publication Publication Date Title
ES2109189B1 (es) Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
KR890701757A (ko) 재조합 아비폭스 바이러스
Verwoerd et al. Orbiviruses
Shaw et al. Protection from IBDV-induced bursal damage by a recombinant fowlpox vaccine, fpIBD1, is dependent on the titre of challenge virus and chicken genotype
Jungmann et al. Apoptosis is induced by infectious bursal disease virus replication in productively infected cells as well as in antigen-negative cells in their vicinity
MX9202724A (es) Composicion que comprende un vector recombinante del agente lelystad y vacuna que comprende la misma.
ES2141081T3 (es) Nuevo aislado de hcv j-1.
ATE144552T1 (de) Rekombinantes geflügelpockenvirus
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
ATE60799T1 (de) Virus-impfstoff.
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
NO933261L (no) Blanding til forsterkning av immunforsvaret
Sato et al. Hemagglutination by calf diarrhea coronavirus
KR100626187B1 (ko) Ｗ／ｏ 에멀젼 면역 보강 비활성 백신의 제조 방법
ATE233821T1 (de) Poxvirusvektoren und deren anwendung als impstoff gegen katzenansteckende peritonitis- viruskrankheit
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
Stott et al. Interaction of bluetongue virus with bovine lymphocytes
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
Hussain et al. Pathogenesis of hemorrhagic enteritis virus infection in turkeys
根本謙 et al. Demonstration of canine herpesvirus-specific hemagglutination.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980101

Kind code of ref document: A1

Effective date: 19980101

FD1A Patent lapsed

Effective date: 20080315